# Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

> **NCT00776503** · PHASE1,PHASE2 · COMPLETED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 52 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** VORINOSTAT

## Key facts

- **NCT ID:** NCT00776503
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776503, "Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00776503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*